AUA University
Advertisement
Cannabis (marijuana) Use in Men with Chronic Prostatitis / Chronic Pelvic Pain Syndrome
Login to Access Video or Poster
Abstract: 1083
Date & Time: May 21, 2012 01:00 PM
Session Title: Infections/Inflammation of the Genitourinary Tract: Prostate & Genitalia
Sources of Funding: Valeant Canada Inc.
Introduction and Objectives
To examine the prevalence of cannabis use among men with CP/CPPS, to estimate the dose size and frequency of cannabis use, and to describe the patient reported indications for its use in this population.
Methods
Parallel online and clinic questionnaire surveys were conducted to assess cannabis use among men with CP/CPPS. As a check on study generalizability, comparisons between the online data (n=365) and clinic data (n=60) showed no clinically meaningful differences in the outcome variables of quality of life (QoL), suicidal ideation, pain and urinary symptoms were evident between these groups.
Results
Forty nine percent of this sample reported cannabis use (n=206). Of those reporting cannabis use, 29% (n=59) indicated use for pain relief (pain users) and 71% (n=147) for recreation. The pain users (mean age=38.26±13.78), were younger than recreational users (42.37±12.18) and individuals who reported never using cannabis (45.29±13.73)(p=.001). More pain users reported cannabis was of pain reduction benefit in comparison to recreational users (Chisq=3.83, p=.05). No differences were found between recreational and pain users in degree of side effects (Chisq=4.43, p=.22), reasons for stopping (Chisq=4.84, p=.18), or use frequency (Chisq=5.48, p=.07). There were no differences in dose smoked between the pain and recreational users (Chisq=5.80, p=.12), but a difference was found in dose eaten between these two groups with 20% of pain users reporting consuming more than 1 gram per dose versus only 7% of recreational users reporting consuming this dosage. (Chisq=12.51,p=.002). Pain users reported more pain (F=4.04, p=.05), poorer CP/CPPS QoL/impact (F=8.61, p=.004), and more suicidal thoughts (F=6.59, p=.01) than recreational users.
Conclusions
Cannabis use is prevalent in men reporting CP/CPPS (49%), but not necessarily used for CP/CPPS symptoms (used for pain in only 29% users). It is important that physicians planning a therapeutic strategy for patients with CP/CPPS know the relevance of this data and question their patients on their use (and effect/impact on symptoms) of marijuana/cannabis. Although this study cannot qualify the benefit or hazard of cannabis use, this is the first study to document the prevalence and patterns of cannabis use in a CP/CPPS population.
Date & Time: May 21, 2012 01:00 PM
Session Title: Infections/Inflammation of the Genitourinary Tract: Prostate & Genitalia
Sources of Funding: Valeant Canada Inc.
Introduction and Objectives
To examine the prevalence of cannabis use among men with CP/CPPS, to estimate the dose size and frequency of cannabis use, and to describe the patient reported indications for its use in this population.
Methods
Parallel online and clinic questionnaire surveys were conducted to assess cannabis use among men with CP/CPPS. As a check on study generalizability, comparisons between the online data (n=365) and clinic data (n=60) showed no clinically meaningful differences in the outcome variables of quality of life (QoL), suicidal ideation, pain and urinary symptoms were evident between these groups.
Results
Forty nine percent of this sample reported cannabis use (n=206). Of those reporting cannabis use, 29% (n=59) indicated use for pain relief (pain users) and 71% (n=147) for recreation. The pain users (mean age=38.26±13.78), were younger than recreational users (42.37±12.18) and individuals who reported never using cannabis (45.29±13.73)(p=.001). More pain users reported cannabis was of pain reduction benefit in comparison to recreational users (Chisq=3.83, p=.05). No differences were found between recreational and pain users in degree of side effects (Chisq=4.43, p=.22), reasons for stopping (Chisq=4.84, p=.18), or use frequency (Chisq=5.48, p=.07). There were no differences in dose smoked between the pain and recreational users (Chisq=5.80, p=.12), but a difference was found in dose eaten between these two groups with 20% of pain users reporting consuming more than 1 gram per dose versus only 7% of recreational users reporting consuming this dosage. (Chisq=12.51,p=.002). Pain users reported more pain (F=4.04, p=.05), poorer CP/CPPS QoL/impact (F=8.61, p=.004), and more suicidal thoughts (F=6.59, p=.01) than recreational users.
Conclusions
Cannabis use is prevalent in men reporting CP/CPPS (49%), but not necessarily used for CP/CPPS symptoms (used for pain in only 29% users). It is important that physicians planning a therapeutic strategy for patients with CP/CPPS know the relevance of this data and question their patients on their use (and effect/impact on symptoms) of marijuana/cannabis. Although this study cannot qualify the benefit or hazard of cannabis use, this is the first study to document the prevalence and patterns of cannabis use in a CP/CPPS population.
Authors
Tripp, Dean (Kingston, Canada); Nickel, J. Curtis; Laura, Katz; Ginting, Jessica V.; Mark, Ware; Santor, Darcy